Biosurgery Market Report 2026

The biosurgery market size has grown strongly in recent years. It will grow from $16.44 billion in 2025 to $17.88 billion in 2026 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to rising volume of surgical procedures, increasing prevalence of chronic wounds, expansion of hospital infrastructure, adoption of modern surgical materials, improvements in biosurgical product safety profiles.

The biosurgery market size is expected to see strong growth in the next few years. It will grow to $24.59 billion in 2030 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to increasing demand for advanced wound care solutions, rising focus on post-surgical complication reduction, expansion of outpatient surgical procedures, growing investments in biosurgical product innovation, increasing adoption of biologics-based surgery aids. Major trends in the forecast period include increasing adoption of advanced hemostatic agents, rising demand for synthetic surgical sealants, growing use of bio-based adhesion barriers, expansion of minimally invasive surgical solutions, enhanced focus on faster wound healing outcomes.

The rising prevalence of chronic diseases is expected to drive the growth of the biosurgery market in the coming years. Chronic diseases are health conditions that persist for a year or more and require ongoing medical care, limiting daily activities, or both. In the United States, chronic diseases such as diabetes, cancer, and heart disease are the leading causes of death and disability. Biosurgery is employed to remove dead tissue, reduce the risk of infection, and accelerate the healing process for chronic wounds. For example, in September 2025, the World Health Organization, a Switzerland-based specialized agency of the United Nations, reported that noncommunicable diseases (NCDs) account for 74% of global deaths. Consequently, the growing prevalence of chronic diseases is fueling the expansion of the biosurgery market.

Key companies in the biosurgery market are utilizing technological advancements, including advanced wound care technology, to improve healing outcomes, lower infection rates, and enhance patient recovery through innovative products and techniques. Advanced wound care technology includes novel methods and products aimed at promoting wound healing, preventing infection, and improving patient outcomes. For instance, in September 2024, Health Care at Home India Pvt Ltd, an India-based medical products manufacturer, launched the WOW (Warriors of Woundcare) Nurses initiative. This program aims to proactively prevent and treat bedsores, a common complication among patients with limited mobility. Bedsores can significantly delay recovery, extend hospital stays, and increase the risk of infection.

In May 2025, Merit Medical Systems, a U.S.-based medical device company specializing in interventional and surgical products, acquired Biolife Delaware LLC for an undisclosed sum. Through this acquisition, Merit intends to expand its biosurgery product offerings by incorporating Biolife’s hemostatic devices, including StatSeal and WoundSeal, thereby strengthening its capabilities in surgical bleeding management. BioLife Delaware is a U.S.-based company that develops and manufactures synthetic hemostatic products for surgical and emergency applications.

Major companies operating in the biosurgery market are Baxter International Inc., B. Braun SE, Becton, Dickinson and Company, Hemostasis LLC, Integra LifeSciences Corporation, Johnson & Johnson Services Inc., CryoLife Inc., Zimmer Biomet Holdings Inc., Kuros Biosciences AG, Orthofix Medical Inc., Smith & Nephew plc, Medtronic plc, Stryker Corp., Tissue Regenix Group plc, Aroa Biosurgery Ltd., Anika Therapeutics Inc., Arthrex Inc., B Braun Surgical SA, Biom’Up SA, Boston Scientific Corporation, Coloplast Corp., Cook Medical Inc., Genzyme Corporation.

North America was the largest region in the biosurgery market in 2025. Asia-Pacific is expected to be the fastest-growing region in the biosurgery market report during the forecast period. The regions covered in the biosurgery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biosurgery market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the biosurgery market by increasing costs of imported biological raw materials, synthetic polymers, sterilization equipment, and precision manufacturing inputs used in hemostats, sealants, and graft substitutes. Hospitals and surgical centers in North America and Europe are most affected due to reliance on imported biosurgical products, while Asia-Pacific faces cost pressure on manufacturing exports. These tariffs are increasing treatment costs and procurement complexity. However, they are also supporting local production, regional sourcing of biomaterials, and expansion of domestic biosurgical manufacturing capabilities.

The biosurgery market research report is one of a series of new reports that provides biosurgery market statistics, including biosurgery industry global market size, regional shares, competitors with a biosurgery market share, detailed biosurgery market segments, market trends and opportunities, and any further data you may need to thrive in the biosurgery industry. This biosurgery market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Biosurgery involves the use of live maggots to eliminate dead tissue from wounds, lower the risk of infection, and promote faster wound healing. It mainly includes semi-synthetic, synthetic, or natural materials that support the healing of surgical incisions and the regeneration of tissue.

The primary biosurgery products include bone-graft substitutes, soft-tissue attachments, hemostatic agents, surgical sealants and adhesives, adhesion barriers, and staple line reinforcement. Bone-graft substitutes consist of natural, synthetic, or composite materials used to fill bone defects and stimulate bone repair. These substitutes are derived from natural or biological sources as well as synthetic sources. They are applied in various procedures, including orthopedic surgery, general surgery, neurological surgery, cardiovascular surgery, gynecological surgery, and more, and are primarily utilized by hospitals, clinics, and other healthcare facilities.

The biosurgery market consists of revenues earned by entities by providing biosurgery services such as maggot therapy, transplantation, and autologous chondrocyte implantation. The market value includes the value of related goods sold by the service provider or included within the service offering. The biosurgery market also includes sales of absorbable hemostats and surgical sealants which are used in providing biosurgery services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.